secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2022-12-06T23:59:59+00:00
Accession:  0001104659-22-124907
Event type: leadership
Sentiment:  positive
Materiality: 0.80
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CSO Francis Plat to retire Dec 31; company details etripamil commercial plan with NDA in mid-2023
--------------------------------------------------------------------------------

- CSO Francis Plat retires Dec 31, 2022; consulting agreement at $15k/month (Stage 1) or $300/hr (Stages 2/3).
- RAPID Phase 3 data: 64% conversion at 30 min (etripamil) vs 31% placebo; median time 17 min vs 54 min.
- NDA submission for etripamil in PSVT expected mid-2023; development in AFib-RVR also underway.
- Initial target market 600,000–900,000 patients; net price estimate $500–$1,000/Rx; cardiologists report 53% adoption.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465922124907/0001104659-22-124907-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465922124907/tm2232091d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-124907

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer